Suggested Topics within your search.
Search alternatives:
"Common drug review clinical review report." » "Common drug review critical review report." (Expand Search)
Showing 1 - 40 results of 205 for search '"Common drug review clinical review report."', query time: 0.26s Refine Results
  1. 1
    Patient group input submissions. Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited).

    Patient group input submissions. Ocrelizumab (Ocrevus) (Hoffmann-La Roche Limited).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  2. 2
    CADTH Canadian Drug Expert Committee final recommendation. Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy.

    CADTH Canadian Drug Expert Committee final recommendation. Mifepristone and misoprostol (Mifegymiso -- Celopharma Inc.) : indication: medical termination of pregnancy.

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  3. 3
    Pharmacoeconomic review report. Mifepristone and misoprostol (Mifegymiso).

    Pharmacoeconomic review report. Mifepristone and misoprostol (Mifegymiso).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  4. 4
    Clinical review report. Mifepristone and misoprostol (Mifegymiso).

    Clinical review report. Mifepristone and misoprostol (Mifegymiso).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  5. 5
    CADTH Canadian Drug Expert Committee final recommendation. Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis.

    CADTH Canadian Drug Expert Committee final recommendation. Sarilumab (Kevzara -- Sanofi Genzyme) : indication: rheumatoid arthritis.

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  6. 6
    Clinical review report. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)

    Clinical review report. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) (Gilead Sciences Canada, Inc.)

    Version: final.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  7. 7
    Clinical review report. Apomorphine (Movapo) (Paladin Labs, Inc.)

    Clinical review report. Apomorphine (Movapo) (Paladin Labs, Inc.)

    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  8. 8
    Clinical review report. Cysteamine delayed-release capsules (Procysbi) Horizon Pharma Ireland Ltd.

    Clinical review report. Cysteamine delayed-release capsules (Procysbi) Horizon Pharma Ireland Ltd.

    Version: final.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  9. 9
    Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).

    Pharmacoeconomic review report. Guselkumab (Tremfya) (Janssen Inc.).

    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  10. 10
    Pharmacoeconomic review report. Empagliflozin and Metformin fixed-dose combination (Synjardy).

    Pharmacoeconomic review report. Empagliflozin and Metformin fixed-dose combination (Synjardy).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  11. 11
    Sarilumab (Kevzara).

    Sarilumab (Kevzara).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  12. 12
    Clinical review report. Dolutegravir (Tivicay).

    Clinical review report. Dolutegravir (Tivicay).

    Published 2014
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  13. 13
    Clinical review report. Tocilizumab (Actemra) (Hoffmann-La Roche Limited).

    Clinical review report. Tocilizumab (Actemra) (Hoffmann-La Roche Limited).

    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  14. 14
    Clinical review report. Guselkumab (Tremfya) (Janssen Inc.)

    Clinical review report. Guselkumab (Tremfya) (Janssen Inc.)

    Version: final.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  15. 15
    CADTH Canadian drug expert committee recommendation. Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension.

    CADTH Canadian drug expert committee recommendation. Latanoprost (Monoprost -- Laboratoires Thea) : indication : glaucoma and ocular hypertension.

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  16. 16
    CADTH Canadian Drug Expert Committee recommendation. Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.

    CADTH Canadian Drug Expert Committee recommendation. Nitisinone (MDK-Nitisinone -- mendeliKABs inc.) : indication : the treatment of adult and pediatric patients with hereditary ty...

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  17. 17
    CADTH Canadian Drug Expert Committee recommendation. Cysteamine delayed-release (Procysbi -- Horizon Pharma Ireland Ltd.) : indication : nephropathic cystinosis.

    CADTH Canadian Drug Expert Committee recommendation. Cysteamine delayed-release (Procysbi -- Horizon Pharma Ireland Ltd.) : indication : nephropathic cystinosis.

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  18. 18
    CADTH Canadian Drug Expert Committee recommendation. Nusinersen (Spinraza -- Biogen Canada Inc.) : indication : treatment of 5q spinal muscular atrophy.

    CADTH Canadian Drug Expert Committee recommendation. Nusinersen (Spinraza -- Biogen Canada Inc.) : indication : treatment of 5q spinal muscular atrophy.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  19. 19
    CADTH Canadian Drug Expert Committee recommendation. Insulin degludec (Tresiba -- Novo Nordisk Canada Inc.) : indication : diabetes mellitus, types I and II.

    CADTH Canadian Drug Expert Committee recommendation. Insulin degludec (Tresiba -- Novo Nordisk Canada Inc.) : indication : diabetes mellitus, types I and II.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  20. 20
    CADTH Canadian Drug Expert Committee recommendation. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) : indication : chronic hepatitis C virus infection.

    CADTH Canadian Drug Expert Committee recommendation. Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) : indication : chronic hepatitis C virus infection.

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  21. 21
    CADTH Canadian Drug Expert Committee recommendation. Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis.

    CADTH Canadian Drug Expert Committee recommendation. Tocilizumab (Actemra - Hoffmann-La Roche Limited) : indication : giant cell arteritis.

    Final.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  22. 22
    CADTH Canadian Drug Expert Committee recommendation. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis C virus infection.

    CADTH Canadian Drug Expert Committee recommendation. Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi -- Gilead Sciences Canada, Inc.) : indication : chronic hepatitis C virus infection...

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  23. 23
    CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.

    CADTH Canadian Drug Expert Committee recommendation. Apomorphine hydrochloride (Movapo -- Paladin Labs Inc.) : indication : Parkinson's disease.

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  24. 24
    CADTH Canadian Drug Expert Committee recommendation. Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemia type-1 in combination with a dietary restriction of tyrosine and phenylalanine.

    CADTH Canadian Drug Expert Committee recommendation. Nitisinone (Orfadin -- Sobi Canada Inc.) : indication: the treatment of adult and pediatric patients with hereditary tyrosinemi...

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  25. 25
    CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

    CADTH Canadian Drug Expert Committee recommendation. Guselkumab (Tremfya -- Janssen Inc.) : indication : for the treatment of adult patients with moderate-to-severe plaque psoriasi...

    Version 1.0.
    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  26. 26
    Patient group input submissions. Empagliflozin and metformin (Synjardy) for diabetes mellitus (Type 2).

    Patient group input submissions. Empagliflozin and metformin (Synjardy) for diabetes mellitus (Type 2).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  27. 27
    CADTH Canadian Drug Expert Committee final recommendation. Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) : indication : type 2 diabetes mellitus.

    CADTH Canadian Drug Expert Committee final recommendation. Empagliflozin / metformin hydrochloride (Synjardy -- Boehringer Ingelheim Canada Ltd.) : indication : type 2 diabetes mel...

    Published 2016
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  28. 28
    Pharmacoeconomic review report. Cysteamine delayed-release capsules (Procysbi), Horizon Pharma Ireland Ltd.

    Pharmacoeconomic review report. Cysteamine delayed-release capsules (Procysbi), Horizon Pharma Ireland Ltd.

    Published 2018
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  29. 29
    CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple sclerosis with active disease defined by clinical and imaging features.

    CADTH Canadian Drug Expert Committee recommendation. Ocrelizumab (Ocrevus -- Hoffmann-La Roche Limited) : indication : treatment of adult patients with relapsing-remitting multiple...

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  30. 30
    CADTH Canadian Drug Expert Committee recommendation. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) : indication : diabetes mellitus, type 2.

    CADTH Canadian Drug Expert Committee recommendation. Lixisenatide (Adlyxine -- Sanofi-Aventis Canada inc.) : indication : diabetes mellitus, type 2.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  31. 31
    CDEC final recommendation. Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) : indication : chronic obstructive pulmonary disease.

    CDEC final recommendation. Tiotropium bromide (Spiriva respimat -- Boehringer Ingelheim Canada Ltd.) : indication : chronic obstructive pulmonary disease.

    Published 2015
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  32. 32
    CDEC final recommendation. Dolutegravir (Tivicay -- ViiV Healthcare ULC) : indication : HIV infection.

    CDEC final recommendation. Dolutegravir (Tivicay -- ViiV Healthcare ULC) : indication : HIV infection.

    Published 2014
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  33. 33
    CADTH CDEC final recommendation. Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.) : indication : Type 2 Diabetes mellitus.

    CADTH CDEC final recommendation. Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.) : indication : Type 2 Diabetes mellitus.

    Published 2015
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  34. 34
    Clinical review report. Propiverine hydrochloride (Mictoryl/Mictoryl pediatric).

    Clinical review report. Propiverine hydrochloride (Mictoryl/Mictoryl pediatric).

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  35. 35
    Patient group input submissions. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Patient group input submissions. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  36. 36
    CADTH Canadian Drug Expert Committee recommendation. Eliglustat (Cerdelga -- Sanofi Genzyme) : indication: Type 1 Gaucher disease.

    CADTH Canadian Drug Expert Committee recommendation. Eliglustat (Cerdelga -- Sanofi Genzyme) : indication: Type 1 Gaucher disease.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  37. 37
    Pharmacoeconomic review report. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Pharmacoeconomic review report. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  38. 38
    Clinical review report. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Clinical review report. Eliglustat (Cerdelga) : (Sanofi Genzyme) : indication: Gaucher disease type 1.

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  39. 39
    Patient group input submissions. AbobotulinumtoxinA (Dysport therapeutic ULS) for the symptomatic treatment of focal spasticity affection the upper limbs in adults.

    Patient group input submissions. AbobotulinumtoxinA (Dysport therapeutic ULS) for the symptomatic treatment of focal spasticity affection the upper limbs in adults.

    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:
  40. 40
    CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) : indication: for the symptomatic treatment of focal spasticity affecting the upper limbs in adults.

    CADTH Canadian Drug Expert Committee recommendation. AbobotulinumtoxinA (Dysport therapeutic -- Ipsen Biopharmaceuticals Canada Inc.) : indication: for the symptomatic treatment of...

    Version 1.0.
    Published 2017
    “…Common drug review clinical review report.…”
    Get full text
    Full text
    Electronic eBook
    Save to List
    Saved in:

Search Tools: